TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$3.95 +0.04 (+1.02%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades About HLS Therapeutics Stock (TSE:HLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HLS Therapeutics alerts:Sign Up Key Stats Today's RangeC$3.90▼C$4.0050-Day RangeC$3.05▼C$3.9952-Week RangeC$3.00▼C$5.48Volume10,298 shsAverage Volume23,895 shsMarket CapitalizationC$125.57 millionP/E RatioN/ADividend Yield5.06%Price TargetC$3.63Consensus RatingHold Company OverviewHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, HLS Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks17th Percentile Overall ScoreHLS MarketRank™: HLS Therapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingHLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHLS Therapeutics has received no research coverage in the past 90 days.Read more about HLS Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about HLS Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HLS. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipHLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth.Read more about HLS Therapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for HLS. News and Social Media1.8 / 5News Sentiment0.28 News SentimentHLS Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for HLS Therapeutics this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$3,828.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 0.37% of the stock of HLS Therapeutics is held by insiders.Percentage Held by Institutions65.20% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HLS Therapeutics' insider trading history. Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HLS Stock News HeadlinesHLS Therapeutics Inc. (TSE:HLS) Shares Could Be 38% Below Their Intrinsic Value EstimateOctober 17 at 11:01 AM | finance.yahoo.comDantech Announces Participation as a Silver Sponsor at BioFuture 2024 in New York CityOctober 14 at 2:08 PM | finance.yahoo.comCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …October 17, 2024 | Weiss Ratings (Ad)HLS Therapeutics Inc (HLTRF) Q2 2024 Earnings Call Highlights: Strategic Growth Amid Revenue ...October 9, 2024 | finance.yahoo.comHLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comHLS Therapeutics Inc. (74D.F)August 23, 2024 | finance.yahoo.comFDA gives thumbs down to MDMA for now, demanding further researchAugust 13, 2024 | msn.comHLS Therapeutics Announces Q2 2024 Financial ResultsAugust 8, 2024 | finance.yahoo.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$3.95 at the beginning of the year. Since then, HLS stock has increased by 0.0% and is now trading at C$3.95. View the best growth stocks for 2024 here. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) posted its earnings results on Thursday, August, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). The firm earned $19.87 million during the quarter, compared to analysts' expectations of $19.25 million. HLS Therapeutics had a negative net margin of 40.90% and a negative trailing twelve-month return on equity of 24.82%. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.63 High Stock Price TargetC$4.00 Low Stock Price TargetC$3.25 Potential Upside/Downside-8.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-24,090,000.00 Net Margins-40.90% Pretax MarginN/A Return on Equity-24.82% Return on Assets-2.89% Debt Debt-to-Equity Ratio100.44 Current Ratio2.02 Quick Ratio1.01 Sales & Book Value Annual SalesC$58.89 million Price / Sales2.13 Cash FlowC$0.26 per share Price / Cash Flow15.22 Book ValueC$2.60 per share Price / Book1.52Miscellaneous Outstanding Shares31,790,000Free FloatN/AMarket CapC$125.57 million OptionableNot Optionable Beta1.07 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (TSE:HLS) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.